Survodutide: A Potential Game-Changer in Obesity and Liver Disease Treatment

Boehringer Ingelheim's experimental drug, survodutide, shows promise in reducing visceral and liver fat with minimal lean mass loss, according to a late-stage study. The drug, obtained from Zealand Pharma, mimics GLP-1 and glucagon proteins, aiming to differentiate itself in the competitive obesity treatment market by offering benefits beyond weight loss.

Boehringer Ingelheim announced promising results for its experimental obesity drug, survodutide, in a late-stage study.

Data indicated significant reductions in visceral and liver fat while maintaining lean mass. Survodutide, licensed from Zealand Pharma, mimics proteins to induce satiety, differentiating itself in a competitive market.

Experts believe survodutide could become a crucial treatment option for obesity linked with liver disease.